Natixis Advisors LLC Raises Stock Holdings in Medtronic PLC $MDT

Natixis Advisors LLC grew its position in shares of Medtronic PLC (NYSE:MDT) by 3.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,695,751 shares of the medical technology company’s stock after buying an additional 77,975 shares during the period. Natixis Advisors LLC owned about 0.21% of Medtronic worth $258,954,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in MDT. Brighton Jones LLC boosted its position in shares of Medtronic by 1,368.0% in the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after buying an additional 37,265 shares during the period. Sivia Capital Partners LLC boosted its position in shares of Medtronic by 9.6% in the second quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after buying an additional 381 shares during the period. Jump Financial LLC acquired a new stake in shares of Medtronic in the second quarter worth $299,000. Main Street Financial Solutions LLC boosted its position in shares of Medtronic by 28.9% in the second quarter. Main Street Financial Solutions LLC now owns 14,356 shares of the medical technology company’s stock worth $1,251,000 after buying an additional 3,218 shares during the period. Finally, HUB Investment Partners LLC boosted its position in shares of Medtronic by 21.3% in the second quarter. HUB Investment Partners LLC now owns 19,226 shares of the medical technology company’s stock worth $1,676,000 after buying an additional 3,376 shares during the period. 82.06% of the stock is owned by institutional investors.

Medtronic Price Performance

NYSE MDT opened at $73.95 on Tuesday. Medtronic PLC has a fifty-two week low of $73.67 and a fifty-two week high of $106.33. The stock’s 50-day moving average is $82.11 and its two-hundred day moving average is $92.49. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. The firm has a market cap of $94.94 billion, a P/E ratio of 20.60, a price-to-earnings-growth ratio of 1.76 and a beta of 0.58.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, April 17th. Investors of record on Friday, March 27th were given a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 3.8%. The ex-dividend date was Friday, March 27th. Medtronic’s payout ratio is 79.11%.

Analyst Upgrades and Downgrades

MDT has been the subject of several recent research reports. Barclays increased their price objective on Medtronic from $118.00 to $120.00 and gave the stock an “overweight” rating in a report on Wednesday, April 1st. Jefferies Financial Group reiterated a “hold” rating and set a $95.00 price objective on shares of Medtronic in a report on Thursday, April 23rd. Mizuho cut their price objective on Medtronic from $125.00 to $120.00 and set an “outperform” rating for the company in a report on Monday, April 13th. Wall Street Zen lowered Medtronic from a “buy” rating to a “hold” rating in a report on Saturday, April 11th. Finally, Robert W. Baird increased their price objective on Medtronic from $92.00 to $93.00 and gave the stock a “neutral” rating in a report on Wednesday, April 15th. Fifteen equities research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $106.45.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).